|

Cadonilimab (AK104) Clinical Trials

6 actively recruiting trials

No change since May 2026

Pipeline

Phase 2: 3Phase 3: 2Phase 1/2: 1

Top Sponsors

  • Akeso2
  • Xin-Hua Xu1
  • Hubei Cancer Hospital1
  • Guangzhou Medical University1
  • Chongqing University Cancer Hospital1

Indications

  • Cancer6
  • Lung Cancer2
  • Resectable Colon Cancer1
  • MSI-H/dMMR Colorectal Cancer1
  • NSCLC (Non-small Cell Lung Cancer)1

Other6 trials

A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer With Negative Driver Genes and Failed Immunotherapy
Phase 2
A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC
Phase 3
Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis
Phase 1/2
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
Phase 3
SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)
Phase 2
Study Of Cadonilimab Combined With Radiotherapy In The Treatment of Locally Advanced Cervical Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.